APYX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
13.9M
+11.2%
12.5M
-34.8%
19.2M
+48.8%
12.9M
+13.2%
11.4M
Cost of Revenue
5.0M
+9.8%
4.6M
-36.3%
7.2M
+56.4%
4.6M
+6.8%
4.3M
Gross Profit
8.9M
+11.9%
7.9M
-34.0%
12.0M
+44.6%
8.3M
+17.1%
7.1M
Operating Expenses
10.7M
+21.3%
8.8M
-26.6%
12.0M
+31.3%
9.1M
-5.5%
9.7M
R&D
793.0K
+3.7%
765.0K
-19.0%
944.0K
+17.9%
801.0K
-2.8%
824.0K
SG&A
9.9M
+22.5%
8.1M
-26.9%
11.0M
+32.6%
8.3M
-5.7%
8.8M
Operating Income
-1804000
-106.2%
-875000
-8054.5%
11.0K
+101.3%
-832000
+67.7%
-2574000
EBITDA
-1608000
-138.9%
-673000
-390.1%
232.0K
+134.7%
-668000
+72.6%
-2442000
Net Income
-3072000
-43.4%
-2143000
-72.8%
-1240000
+36.6%
-1955000
+47.7%
-3738000
EPS (Basic)
$-0.07
-40.0%
$-0.05
-66.7%
$-0.03
+40.0%
$-0.05
+44.4%
$-0.09
EPS (Diluted)
$-0.07
-40.0%
$-0.05
-66.7%
$-0.03
+40.0%
$-0.05
+44.4%
$-0.09
Shares (Diluted)
43.9M
+0.2%
43.7M
+3.7%
42.2M
+3.5%
40.7M
+0.0%
40.7M
Apyx Medical (APYX) โ€” Financials